A German company, Medigene AG, announced that TCR-T therapy was entering clinical trials for I / II.

Germany's Biomass AG recently announced that TCR-T cell candidate therapy MDG1011 has been the first patient to treat acute myeloid leukemia (AML) in an I / II clinical trial for hematologic tumors.

MDG1011 was designed as a single-use regimen that calibrates tumor antigen PRAME (an antigen expressed primarily in melanoma) in T cell targets using a T cell receptor (TCR) from a patient source. And one patient with multiple myeloma.. 

Dr. Kai Pinkernell of Medigene says hematologic malignancies such as terminal AML, MDS and MM are difficult to treat and patient prognosis is usually poor. "We hope that our TCR treatment will be a new treatment option for severely ill patients. The first patient utilization is a very important step in the development of this new candidate therapy. "

Medigene is dedicated to developing individualized T cell immunotherapy. The fastest studies are T cell receptor-modulated T cells (TCR-T) therapy MDG1011, and dendritic cell vaccine (DC). 

Medigene's TCR-T technology has received attention from the medical community. 

 On May 14, 2018, bluebird bio announced a strategic consortium with Medigene AG, a German biotechnology company, to focus on research and development of TCR-T cell immunotherapy for cancer.

Under the agreed amendment, the number of target antigen / MHC restriction combinations of specific TCR potential candidate products found through Medigene increases from four to six. As part of the contract extension, Medigene will receive a separate batch of $ 8 million. Will allow Medigene to receive a monetary amount of $ 1.5 billion. 

Previously, Medigene found TCRs on the TCR technology platform in accordance with the terms of the agreement, which was signed in September 2016, to allow bluebird bio to screen. After the non-clinical R & D collaboration, bluebird bio will assume full responsibility for the clinical, clinical development and commercialization of TCR-T cell candidate drug candidates and will receive exclusive license for intellectual property rights covering selected TCRs.